Temozolomide (TMZ)-resistant glioblastoma multiforme (GBM) cells exhibit mesenchymal and stemness traits and resist erastin-induced ferroptosis by activating the CYBB/NRF2/SOD2 pathway (86). Here, SOD2 is linked to glioblastoma.